Botulinum Toxin Therapy for Acute and Chronic Pain in Hair Transplant Surgery

2020 ◽  
Vol 30 (2) ◽  
pp. 50-51
Author(s):  
Samuel M. Lam
1991 ◽  
Vol 9 (1) ◽  
pp. 205-224 ◽  
Author(s):  
Peter J. Savino ◽  
Marlon Maus

2006 ◽  
Vol 117 ◽  
pp. 124
Author(s):  
E. Milano ◽  
M. Coletti Moja ◽  
F. Celotto ◽  
C. Favarato ◽  
A. Mauro ◽  
...  

2013 ◽  
Vol 11 (8) ◽  
pp. 657
Author(s):  
Zoltan Mari ◽  
Gopiga Thanabalasundaram ◽  
Eric Farbman ◽  
Barbara Karp ◽  
Mark Hallett

2007 ◽  
Vol 44 (7) ◽  
pp. 398-401
Author(s):  
Makoto RYU ◽  
Hideaki KUBOTA ◽  
Yutaka OKETANI ◽  
Yumi ITO ◽  
Hiromichi HARA

2008 ◽  
Vol 29 (5) ◽  
pp. 333-338 ◽  
Author(s):  
Pasquale Capaccio ◽  
Sara Torretta ◽  
Maurizio Osio ◽  
Davide Minorati ◽  
Francesco Ottaviani ◽  
...  

2018 ◽  
Vol 2 (3) ◽  
Author(s):  
Raj Kumar

Botulinum toxin is one of the most potent molecule known to mankind. A neurotoxin, with high affinity for cholinergic synapse, is effectively capable of inhibiting the release of acetylcholine. On the other hand, botulinum toxin is therapeutically used for several musculoskeletal disorders. Although most of the therapeutic effect of botulinum toxin is due to temporary skeletal muscle relaxation (mainly due to inhibition of the acetylcholine release), other effects on the nervous system are also investigated. One of the therapeutically investigated areas of the botulinum neurotoxin (BoNT) is the treatment of pain. At present, it is used for several chronic pain diseases, such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Although the effect of botulinum toxin in pain is mainly due to its effect on cholinergic transmission in the somatic and autonomic nervous systems, research suggests that botulinum toxin can also provide benefits related to effects on cholinergic control of cholinergic nociceptive and antinociceptive systems. Furthermore, evidence suggests that botulinum toxin can also affect central nervous system (CNS). In summary, botulinum toxin holds great potential for pain treatments. It may be also useful for the pain treatments where other methods are ineffective with no side effect(s). Further studies will establish the exact analgesic mechanisms, efficacy, and complication of botulinum toxin in chronic pain disorders, and to some extent acute pain disorders.


2013 ◽  
Vol 15 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Gael J. Yonnet ◽  
Anette S. Fjeldstad ◽  
Noel G. Carlson ◽  
John W. Rose

Bladder dysfunction in multiple sclerosis (MS) can be socially disabling, have negative psychological and economic consequences, and impair patients' quality of life. Knowledge of the functional anatomy and physiology of the urinary tract is essential to understand the symptoms associated with central nervous system lesions and the pharmacotherapies used to treat them. Treatments for neurogenic detrusor overactivity (NDO) have consisted mainly of administration of anticholinergic drugs, which have been shown to provide suboptimal clinical benefits and be poorly tolerated. The US Food and Drug Administration (FDA) approval of intravesicular botulinum toxin therapy provides a second-line option for MS patients with NDO not responsive to anticholinergic drugs. We performed a review of key literature pertaining to the intravesicular application of botulinum toxin. In the management of NDO, administration of intravesicular botulinum toxin using clean intermittent catheterization decreases the incidence of urinary tract infections, promotes urinary continence, and improves quality of life for 9 months after a single injection; moreover, those benefits are maintained with repeated injections over time.


Sign in / Sign up

Export Citation Format

Share Document